Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Novartis files regulatory dossiers for Zometa around the world

Dec. 27, 1999

PPD GenuPro retains rights to dapoxetine for treatment of premature ejaculation

Dec. 23, 1999

Major regulatory filings made for unique antidiabetic medication

Dec. 22, 1999

Acute and chronic effects of two new TZDs on glucose metabolism examined in rats

Dec. 22, 1999

New agents for diabetes in development at Otsuka

Dec. 22, 1999

Statins as new approach to the treatment of bone loss diseases

Dec. 22, 1999

Licensing opportunity from NIH: glycoprotein hormone superagonists

Dec. 22, 1999

GRF analogue expected to proceed to phase II trials in 2000

Dec. 21, 1999

Japanese launch announced for Actos; other antidiabetic agents in the pipeline

Dec. 21, 1999

Benzimidazole antidiabetic agent advances through the pipeline in Japan and overseas

Dec. 20, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 2, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
BMS’ mezigdomide doubles PFS in multiple myeloma
BioWorld
Bristol Myers Squibb Co. disclosed in March 2026 that the phase III portion of the seamless phase II/III Successor-2 study testing mezigdomide in combination with...
ADCs, multispecific antibodies anchor $10B Pfizer-Innovent deal
BioWorld
Pfizer Inc. is paying Innovent Biologics Co. Ltd. $650 million up front and up to $9.85 billion in milestones, plus royalties, to collaborate across 12 early...